These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 23466576)

  • 61. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.
    Hodges JC; Das P; Eng C; Reish AG; Beddar AS; Delclos ME; Krishnan S; Crane CH
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):791-4. PubMed ID: 19231109
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
    Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
    Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Twenty-five-year experience with radical chemoradiation for anal cancer.
    Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation.
    Liu WS; Hsin CH; Chou YH; Liu JT; Wu MF; Tseng SW; Lee JK; Tseng HC; Wang TH; Su MC; Lee H
    BMC Cancer; 2010 Mar; 10():102. PubMed ID: 20298550
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure.
    Daly ME; Le QT; Maxim PG; Loo BW; Kaplan MJ; Fischbein NJ; Pinto H; Chang DT
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1339-46. PubMed ID: 19540068
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.
    de Meric de Bellefon M; Lemanski C; Castan F; Samalin E; Mazard T; Lenglet A; Demontoy S; Riou O; Llacer-Moscardo C; Fenoglietto P; Aillères N; Thezenas S; Debrigode C; Vieillot S; Gourgou S; Azria D
    Radiother Oncol; 2020 Mar; 144():141-147. PubMed ID: 31809980
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
    Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of advancing age on treatment and outcomes in anal cancer.
    Foo M; Link E; Leong T; Chu J; Lee MT; Chander S; Tran PK; Tomaszewski JM; Michael M; Heriot A; Ngan SY
    Acta Oncol; 2014 Jul; 53(7):909-16. PubMed ID: 24456502
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The prognostic factors following the simultaneous radiochemotherapy of anal canal carcinoma in a multicenter series of 139 patients].
    Grabenbauer GG; Panzer M; Hültenschmidt B; Döker R; Huber K; Kuhne-Velte HJ; Hutter M; Rühl U; Budach V; Wendt T
    Strahlenther Onkol; 1994 Jul; 170(7):391-9. PubMed ID: 8052938
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Continuous-course reirradiation with concurrent carboplatin and paclitaxel for locally recurrent, nonmetastatic squamous cell carcinoma of the head-and-neck.
    Kharofa J; Choong N; Wang D; Firat S; Schultz C; Sadasiwan C; Wong S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):690-5. PubMed ID: 22112556
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
    White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
    Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Haematotoxicity in IMRT/VMAT curatively treated anal cancer.
    Lohynská R; Nýdlová A; Drbohlavová T; Mazaná E; Jirkovská M; Veselský T; Malinová B; Stankušová H
    Klin Onkol; 2020; 33(4):288-294. PubMed ID: 32894958
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
    Hauerstock D; Ennis RD; Grossbard M; Evans A
    Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
    Roohipour R; Patil S; Goodman KA; Minsky BD; Wong WD; Guillem JG; Paty PB; Weiser MR; Neuman HB; Shia J; Schrag D; Temple LK
    Dis Colon Rectum; 2008 Feb; 51(2):147-53. PubMed ID: 18180997
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Munoz F; Rondi N; Morino M; Racca P; Ricardi U
    Br J Radiol; 2016; 89(1060):20150832. PubMed ID: 26838953
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.